Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
38.009,18 +380,70 (+1,01%) EUR/USD
1,0730 -0,0003 (-0,03%) Bitcoin EUR
60.034,64 +48,35 (+0,08%) CMC Crypto 200
1.388,49 +5,91 (+0,43%)
Comera Life Sciences Holdings, Inc. (CMRA)
| Chiusura precedente | 0,0410 |
| Aperto | 0,0215 |
| Denaro | 0,0000 x 2200 |
| Lettera | 0,0000 x 1800 |
| Min-Max giorno | 0,0215 - 0,0400 |
| Intervallo di 52 settimane | 0,0215 - 0,8260 |
| Volume | |
| Media Volume | 21.667 |
| Capitalizzazione | 1,11M |
| Beta (5 anni mensile) | 0,39 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2200 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireComera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass. Yuhong Zeng, Ph.D., Director of Formulation at Comera,
- GlobeNewswire
Comera Life Sciences Announces the Completion of $4.1 Million Private Placement
WOBURN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has completed its previously announced $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share. The shares ar
- GlobeNewswire
Comera Life Sciences Announces Publication of Study Reinforcing Caffeine’s Viscosity Reducing Capabilities
Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies WOBURN, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced the peer-reviewed publication of preclinical data in the Journal of Pharmac
